Search Results - pablo+engel

1 Results Sort By:
Recombinant fusion proteins and complement inhibitors targeting P-selectin, and therapeutic and diagnostic application
Technology: Inventors at MUSC have designed fusion proteins to treat inflammatory and other related pathologies by binding p-selectin (PSel) and modulating complement. Although targeting complement has shown great promise in treating numerous pathologies which has also led to the approval of multiple drugs (e.g. eculizumab, Berinert, Cinryze), targeting...
Published: 2/16/2021   |   Inventor(s): Stephen Tomlinson, Ali Alawieh, Pablo Engel
Category(s): Therapeutic
© 2022. All Rights Reserved. Powered by Inteum